Autologous T cell therapy against CD19: Phase II started

Kite began the open-label, U.S. Phase II ZUMA-2 trial to evaluate a single infusion of KTE-C19 in about 70 patients who received conditioning chemotherapy with fludarabine and cyclophosphamide. ...